Non-invasive prenatal testing for Down's Syndrome reduces the risk of miscarriage and makes prenatal diagnosis for these conditions safer and accessible.

In 2014, the researchers say, 32% of prenatal diagnostic tests for monogenic disorders in their laboratory were non-invasive. NIPD for single gene disorders in a fetus is diagnostic, as it targets specific genetic changes seen in a high risk family. Thus, it would remove the need for invasive testing completely, reducing the risk of miscarriage and making prenatal diagnosis for these conditions safer and more accessible to families who would not otherwise be prepared to take the risk.
Source-ANI